Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ContraVir's James Sapirstein Interviewed On Future Of Combination Therapy In HBV

Executive Summary

At BioPharm America 2016, ContraVir CEO James Sapirstein explains how CMX157, a lipid formulation of tenofovir (Gilead's Viread for HIV and hepatitis B), could become a backbone agent for advances in combination therapy in hep B.

You may also be interested in...



ContraVir Hopes To Establish Backbone For Hepatitis B Combo Therapy

Two deals have resulted in the formerly shingles-focused biotech beginning to build an HBV pipeline and look ahead to therapeutic advances similar to those seen in HIV and hepatitis C. But the New Jersey biotech will be competing with some deep-pocketed competitors in the space.

ContraVir Strikes Deal With Rival Early Stage Hep B Drug Developer

ContraVir Pharmaceuticals Inc. is merging with competitor early stage hepatitis B drug developer Ciclofilin Pharmaceuticals to strengthen its pipeline offering in antivirals.

Tech Transfer Roundup: Athenex, PDS Align With National Cancer Institute On Oncology R&D

Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.

Topics

Related Companies

UsernamePublicRestriction

Register

SC097427

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel